For example, according to the results of the Impower110 study, immunotherapy in advanced NSCLC has extended OS by approximately 3–7 months, with greater benefits observed in patients exhibiting high PD-L1 expression levels [3]. Here, CD274 is linked to non-small cell lung carcinoma.